NCT07700992 A Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring
| NCT ID | NCT07700992 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Università Vita-Salute San Raffaele |
| Condition | Familial Pancreatic Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2026-06-03 |
| Primary Completion | 2031-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2026-06-03 with a primary completion date of 2031-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by an asymptomatic early phase, late diagnosis, and poor survival, particularly in individuals who develop disease outside the context of early-stage detection. Early detection strategies are currently limited to imaging-based surveillance (MRI and endoscopic ultrasound) in selected high-risk populations, but these approaches are invasive, costly, and suboptimal in sensitivity. The aim of this study is to evaluate circulating cell-free and exosome-bound microRNAs as non-invasive biomarkers of PDAC risk and disease biology
Eligibility Criteria
Inclusion Criteria: * Adult men or women aged ≥18 years at the time of plasma sample collection. * Classification as at increased risk for pancreatic ductal adenocarcinoma (PDAC) due to familial pancreatic cancer or hereditary pancreatic cancer syndrome * Classification as at increased risk for pancreatic ductal adenocarcinoma (PDAC) due to the presence of one (or more) mucinous pancreatic cystic lesion(s). * Availability of stored plasma samples collected as part of routine clinical care or surveillance and archived in the institutional biobank. * Availability of relevant clinical and demographic data in institutional medical records sufficient to address study objectives. * Prior provision of informed consent for biobanking and research use of biological samples and data Exclusion Criteria: * Absence or insufficient quality/quantity of stored plasma samples for laboratory analysis. * Lack of clinical data required for cohort classification and/or outcome assessment. * History of pancreatic surgery or interventional procedures prior to plasma sample collection. * Concurrent active malignancy at the time of sample collection, other than non-melanoma skin cancer. * Samples collected outside routine clinical care or not compliant with institutional biobanking and data protection policies.
Contact & Investigator
Alessandro Mannucci, MD
PRINCIPAL INVESTIGATOR
Università Vita-Salute San Raffaele
Frequently Asked Questions
Who can join the NCT07700992 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Familial Pancreatic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07700992 currently recruiting?
Yes, NCT07700992 is actively recruiting participants. Contact the research team at mannucci.alessandro@hsr.it for enrollment information.
Where is the NCT07700992 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT07700992 clinical trial?
NCT07700992 is sponsored by Università Vita-Salute San Raffaele. The principal investigator is Alessandro Mannucci, MD at Università Vita-Salute San Raffaele. The trial plans to enroll 600 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.